An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
AtriCure, Inc. (NASDAQ: ATRC) has launched the EnCompass Clamp® as part of its Isolator Synergy™ Ablation System in the U.S. The clamp received FDA 510(k) clearance for cardiac tissue ablation during surgery, enhancing efficiency in concomitant ablation procedures. Key features include parallel closure, uniform pressure, and a magnetic guide for easier placement. CEO Michael Carrel highlighted its innovative design to improve surgical outcomes, while Dr. Prem Samuel praised its efficiency in minimizing tissue dissection and achieving effective results in a single maneuver.
Positive
Launch of the EnCompass Clamp to enhance ablation efficiency.
FDA 510(k) clearance signifies regulatory approval for surgical use.
Features like parallel closure and a magnetic guide improve usability and results.
Negative
None.
New clamp is designed to improve efficiency of concomitant ablation procedures
MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has launched the EnCompass Clamp®, a part of the Isolator Synergy™ Ablation System in the United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.
The EnCompass Clamp includes features such as parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF). The new features of the EnCompass Clamp allow for easier placement using a magnetic guide, which enables more efficient procedures by minimizing tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are passionate about innovation, leading to high-quality options for our physician partners. We believe the EnCompass Clamp will meet the unique needs of surgeons who are performing closed-atrium cardiac surgery.”
“This new device has become an invaluable part of the way I perform surgical ablation,” said Dr. Prem Samuel, a cardiothoracic surgeon at Midwest Heart & Vascular Specialists, Kansas City, Missouri. “It is used with minimal dissection and creates lesions around the pulmonary veins and the entire posterior wall of the left atrium without opening the atrium, all in a single pass through the transverse and oblique sinuses. I’ve seen firsthand the gains in efficiency that the EnCompass Clamp can bring to my practice and patients.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
Angie Wirick AtriCure, Inc. Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Valerie Storch-Willhaus AtriCure, Inc. Vice President, Corporate Marketing and Communications (612) 424-8359
vstorch-willhaus@atricure.com
Source: AtriCure, Inc.
FAQ
What is the EnCompass Clamp launched by AtriCure?
The EnCompass Clamp is a new device designed for improved efficiency in cardiac tissue ablation during surgery, part of the Isolator Synergy™ Ablation System.
When did AtriCure launch the EnCompass Clamp?
AtriCure announced the launch of the EnCompass Clamp on the day of the press release.
What regulatory approval has the EnCompass Clamp received?
The EnCompass Clamp received FDA 510(k) clearance for use in cardiac surgery.
How does the EnCompass Clamp improve surgical procedures?
It offers features like parallel closure and a magnetic guide that enable easier placement and minimize tissue dissection during surgery.
What does the launch of the EnCompass Clamp mean for AtriCure's market position?
The launch may strengthen AtriCure's position in the cardiac surgery market by offering innovative solutions for atrial fibrillation treatment.
